VIP (Vasoactive Intestinal Peptide): Complete Research Guide UAE (2026)

VIP (Vasoactive Intestinal Peptide): Complete Research Guide UAE (2026)

VIP (Vasoactive Intestinal Peptide): Complete Research Guide UAE (2026)

Vasoactive Intestinal Peptide (VIP) is a 28 amino acid neuropeptide with one of the broadest biological profiles of any research peptide — acting simultaneously as a neurotransmitter, vasodilator, immune modulator, and gut regulator. Its potent anti-inflammatory properties via VPAC receptors make it one of the most studied peptides for autoimmune, inflammatory bowel, and pulmonary research. This guide covers VIP's mechanism, forms, dosing, and UAE availability.

VIP's Mechanisms of Action

Anti-Inflammatory Pathway (VPAC1)

VIP binds predominantly to VPAC1 receptors (expressed on immune cells, gut epithelium, and lung tissue), activating adenylyl cyclase and raising intracellular cAMP. This cascade:

  • Inhibits NF-κB activation — suppressing pro-inflammatory cytokines (TNF-α, IL-6, IL-12, NO)
  • Promotes IL-10 production — shifting the immune environment toward anti-inflammatory resolution
  • Inhibits macrophage activation and dendritic cell maturation — reducing the innate inflammatory cascade

Gut Motility Regulation

VIP is a major non-adrenergic, non-cholinergic (NANC) neurotransmitter in the enteric nervous system. It relaxes intestinal smooth muscle, regulates intestinal secretion, and modulates the gut-brain axis. Research applications include inflammatory bowel disease (IBD), Crohn's disease, and gut dysmotility models.

Pulmonary Research

VIP receptors are densely expressed in bronchial smooth muscle. VIP causes bronchodilation via cAMP-mediated smooth muscle relaxation — with potential applications in pulmonary hypertension and asthma research where current pharmacology is insufficient.

VIP Research Dosing

Form Dose Notes
Injectable (SC/IV) 5 mg vial, 50–200 mcg per dose Very short half-life (~2 min IV); SC extends duration
Nasal spray 5 mg vial Bypasses rapid systemic clearance; preferred for CNS/mucosal applications
Half-life note: VIP has an extremely short IV half-life (~2 minutes) due to rapid peptidase degradation in circulation. Subcutaneous injection significantly extends the effective duration. Intranasal delivery provides direct mucosal and CNS access, bypassing rapid systemic clearance entirely — making the spray format particularly relevant for respiratory and CNS applications.

Key VIP Research Applications

  • Inflammatory Bowel Disease (IBD/Crohn's): VIP reduces intestinal inflammation in multiple IBD models by suppressing macrophage activation and promoting mucosal barrier repair
  • Pulmonary hypertension: VIP deficiency has been documented in pulmonary hypertension patients; replacement therapy reduces pulmonary vascular resistance in research models
  • Rheumatoid arthritis: VIP suppresses synovial inflammation and joint destruction in collagen-induced arthritis models via VPAC1-mediated cytokine regulation
  • Autism spectrum / social behaviour: Emerging research (PANS/PANDAS, social cognition) suggests VIP modulates oxytocin release and social behaviour circuits — a newer research frontier
  • Circadian rhythm: VIP is the primary signal molecule of the suprachiasmatic nucleus (SCN) — the brain's master clock — making it relevant for circadian disruption research common in UAE shift workers

Buy VIP Peptide in Dubai & UAE

Injectable and spray formats — ≥99% HPLC purity, cGMP sourced, COA available.

Shop VIP

Frequently Asked Questions

Why is VIP's half-life so short?

VIP is rapidly degraded by peptidases in the bloodstream, giving it a plasma half-life of ~2 minutes when administered IV. This is why subcutaneous injection (which creates a depot) and intranasal delivery (which targets local tissues directly) are preferred research routes — both avoid the rapid systemic clearance that limits IV utility.

How does VIP compare to BPC-157 for gut inflammation?

VIP and BPC-157 both show anti-inflammatory effects in the gut but through different mechanisms. VIP acts via VPAC receptor cAMP signalling to suppress cytokine production. BPC-157 promotes structural tissue repair, angiogenesis, and growth factor signalling. They are often studied as complementary — VIP for acute inflammation suppression, BPC-157 for structural healing.

Is VIP related to PACAP?

Yes — VIP and PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) are structurally related neuropeptides that both bind VPAC1 and VPAC2 receptors. PACAP additionally binds the PAC1 receptor with higher affinity. They have overlapping but distinct research profiles.

Bacteriostatic water 10 ml
Need bacteriostatic water to reconstitute this peptide?

CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.

Shop Bacteriostatic Water →

Disclaimer: This article is for educational and research purposes only. Products mentioned are research compounds not approved by UAE MOHAP or the FDA for human therapeutic use. Nothing herein constitutes medical advice. Consult a licensed UAE healthcare professional before beginning any peptide protocol.

CS

Written by Core Sup Research Team

Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE

Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.

✓ Research-Based ✓ UAE Market Expert ✓ Medically Reviewed ✓ Lab-Tested Products

Last reviewed: April 2026 · About Core Sup

Back to blog